News

Exciting Data on Rare Endocrine Disorders Unveiled Soon

Exciting Data on Rare Endocrine Disorders Unveiled Soon

Ascendis Pharma to Present Breakthrough Findings at ESPE & ESE 2025

Ascendis Pharma A/S (Nasdaq: ASND) has announced plans to present cutting-edge data concerning its hypoparathyroidism, achondroplasia, and growth hormone deficiency (GHD) programs at the upcoming joint congress of the European Society for Paediatric Endocrinology (ESPE) and the European Society of Endocrinology (ESE). Set to take place in Copenhagen from May 10-13, 2025, this congress will serve as a platform for the latest advancements in rare endocrine disease treatment.

Insights into Clinical Trials and Presentations

During the congress, Ascendis will host a series of four oral presentations shedding light on their clinical trial results. Highlights will include:

  • A comprehensive overview of 4-year efficacy and safety data from the Phase 2 PaTH Forward Trial focusing on TransCon PTH (palopegteriparatide) for adults with chronic hypoparathyroidism.
  • Week 52 growth and bone morphometry data derived from the pivotal ApproaCH Trial of TransCon CNP (navepegritide) in children diagnosed with achondroplasia.
  • Robust efficacy and safety data from the Phase 3 foresiGHt Trial involving TransCon hGH (lonapegsomatropin) for adults suffering from growth hormone deficiency.

Dr. Aimee Shu, Executive Vice President of Endocrine & Rare Disease Medical Science and Chief Medical Officer at Ascendis, expressed her excitement, stating, "We are thrilled to present promising data that underscore the clinical benefits of our innovative therapies to the key opinion leaders attending ESPE & ESE 2025."

Schedule of Presentations and Discussions

Throughout the congress, Ascendis Pharma will be engaged in numerous presentations and discussions:

Hypoparathyroidism

  • Sunday, May 11, 09:55 - 10:25 CEST: Product Theater - Restoring Physiological Levels of PTH in Chronic Hypoparathyroidism
  • Sunday, May 11, 16:55-17:55 CEST: Poster Hall - Estimating the Risk of Chronic Kidney Disease Progression in Chronic Hypoparathyroidism: A Retrospective Matched Cohort Study
  • Monday, May 12, 13:00 - 14:30 CEST: Room D5 - Beyond Conventional Care: Redefining Treatment Success in Chronic Hypoparathyroidism
  • Monday, May 12, 15:55-16:05 CEST: Room C2 - Long-Term Efficacy & Safety of Palopegteriparatide Treatment in Adults with Chronic Hypoparathyroidism: Findings from the Phase 2 PaTH Forward Trial

Achondroplasia

  • Sunday, May 11, 15:55-17:25 CEST: Room C2 - Assessing HRQoL in Achondroplasia Across the Life Course
  • Monday, May 12, 15:15-15:25 CEST: Room C2 - Effects of Navepegritide on Bone Morphometry in Children with Achondroplasia: Results from the ApproaCH Clinical Trial
  • Tuesday, May 13, 15:05-15:15 CEST: Room D2 - Effects of Navepegritide on Growth in Children with Achondroplasia: Results from the ApproaCH Clinical Trial

Growth Hormone Deficiency

  • Tuesday, May 13, 14:45-14:55 CEST: Room D2 - Results of the foresiGH Trial Support the Efficacy and Safety of Once-Weekly Lonapegsomatropin in Adults with GHD

Understanding Hypoparathyroidism, Achondroplasia, and GHD

Hypoparathyroidism is a significant endocrine disorder characterized by low parathyroid hormone (PTH) levels, affecting the body's ability to regulate calcium and phosphate effectively. This leads to numerous complications such as neuromuscular irritability and cognitive impairment. Most cases arise post-surgery, while others stem from autoimmune conditions.

On the other hand, achondroplasia is a genetic condition affecting bone growth, with wide-ranging systemic impacts beyond skeletal dysplasia, including muscular and neurological complications. It affects many individuals and requires ongoing medical attention to manage its effects through various life stages.

Growth hormone deficiency (GHD) can severely impact adults, leading to metabolic issues, increased body fat, impaired quality of life, and psychological challenges. The availability of innovative therapies like those offered by Ascendis Pharma presents a ray of hope for these conditions.

About Ascendis Pharma A/S

Ascendis Pharma is dedicated to leveraging its TransCon technology platform to offer innovative treatments aimed at improving patient outcomes. With a commitment to excellence anchored in their values of patients, science, and passion, Ascendis Pharma strives to develop therapies that are not only effective but also transformative. The company operates globally, with its headquarters situated in Copenhagen, Denmark.

Frequently Asked Questions

What is the focus of Ascendis Pharma's upcoming presentations?

Ascendis Pharma will present new data on hypoparathyroidism, achondroplasia, and growth hormone deficiency during ESPE & ESE 2025.

When and where will the congress occur?

The joint congress will take place from May 10-13, 2025, in Copenhagen.

Who will be presenting the findings?

A selection of presentations will be conducted by top experts, including Dr. Andrea Palermo and Dr. Leanne Ward, among others.

What conditions are being addressed by Ascendis Pharma?

Ascendis is focusing on conditions such as hypoparathyroidism, achondroplasia, and growth hormone deficiency.

How can I learn more about Ascendis Pharma's work?

For further details, you can visit Ascendis Pharma's official website, where they share comprehensive information about their innovative approaches and clinical studies.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Rehab Equipment Growth Meets a Brutal Access Gap

Updated Category News Views 89

Rehabilitation demand is piling up faster than the equipment can reach people. That is the uncomfortable fact sitting beneath Wissen Research's forecast for a global rehabilitation equipment market rising from $19.1 billion in 2026 to $25.8 billion by 2031, a 6.2% annual growth rate. It is a respectable expansion story, not some rocket-ship fairy tale. More important, it...

Continue Reading
Precision Metal Forming Is Industry's Quiet Backbone

Updated Category News Views 88

A fraction of a millimeter can turn a perfectly good industrial part into an expensive headache. That unglamorous reality sits at the center of Michele Caulfield's discussion of precision metal forming for HelloNation, and it deserves more attention than it usually gets. Investors watching manufacturing tend to chase flashy automation headlines, big aerospace orders, or...

Continue Reading
A Parish Memoir That Sends Its Proceeds Back Home

Updated Category News Views 114

Some books arrive with a thunderclap; this one shows up carrying a folding chair, a prayer book, and a memory that refuses to leave. You Give Them Something to Eat, the new memoir from Fr. Michael J Rieder, is built from more than a hundred short chapters rather than one grand, polished life story. That choice fits the material. Parish life is rarely a clean parade of...

Continue Reading
DocLinq Takes Aim at Care Gaps Between Office Visits

Updated Category News Views 149

Healthcare's most expensive loose ends often pile up after the appointment ends. DocLinq, launched from Columbia, Maryland, is taking a run at that awkward stretch between office visits, where records sit in separate systems, chronic-care follow-up gets uneven, and patients are expected to remember far more than any human reasonably can. This is not a story about AI...

Continue Reading
Parents Hand Kids Devices Years Before They Intended

Updated Category News Views 286

A nine-year-old with a smartphone used to raise eyebrows; this survey says it is increasingly the household baseline. All About Cookies, working with parental-control company Bark, surveyed U.S. parents and found that children typically receive personal devices well before their parents believe they should. That mismatch is not some cute little parenting contradiction. It...

Continue Reading
CloudBackend's €6.6M Test: Can Vibe Code Become SaaS?

Updated Category News Views 108

A prototype is cheap theatre; keeping it alive after customers arrive is where the bill lands. CloudBackend has raised €6.6 million to attack that unglamorous, absolutely vital stretch between an AI-made app and an actual software business. The round is led by Carl-Henric Svanberg's family office, while existing backer M2 Asset Management increased its stake. That is a...

Continue Reading
Snowrise Targets the Blind Spots in CPG Sales Data

Updated Category News Views 128

A sales total can look healthy while the floorboards are quietly rotting underneath it. That is the uncomfortable CPG problem Snowrise is aiming at: brands know what moved last quarter, but often cannot identify which stores, channels, communities, or promotions actually created the result. Plenty of management teams still steer by topline revenue, net distribution gains,...

Continue Reading
Hanmi Compressor Tests Vietnam Before Wider Expansion

Updated Category News Views 125

Compressed air is the sort of factory necessity nobody brags about until it fails, and that is precisely why Hanmi Compressor’s Vietnam plan deserves a sober look. The Daegu-based specialist is not arriving with a grand export victory lap. It is still building the front door: a website, a promotional video, and a process for finding Vietnamese manufacturers and...

Continue Reading
Resolve Adds Cahaba in Birmingham Pain-Care Expansion

Updated Category News Views 36

Pain-care consolidation has a peculiar way of looking tidy in a release and messy in the real world. Resolve Pain Solutions announced on November 18, 2026, that it has acquired Cahaba Pain and Spine Care, an established provider serving greater Birmingham, Alabama. On its face, this is a straightforward expansion move: buy a respected local practice, retain its physician...

Continue Reading
Excel Treatment Center Adds ART Trauma Therapy Option

Updated Category News Views 117

Trauma rarely arrives at an addiction program wearing a name tag. Excel Treatment Center in Dover, New Jersey, is responding to that uncomfortable reality by adding Accelerated Resolution Therapy® (ART) to the individual, group, and family therapy already available to its clients. The center says its therapists have completed ART training, and the approach is now part of...

Continue Reading

Top 5 Most Recently Viewed Articles

Current Trends in Short Interest Impacting PayPal Stock

Updated Category News Views 262

Understanding PayPal Holdings Inc and Its Market Position PayPal Holdings Inc (NYSE: PYPL) remains a prominent player in the digital payments space, continuing to see fluctuations in its market sentiment. Recently, the company has noted a significant increase in short interest as a percentage of float, climbing by 11.57%. This rise has brought the total number of shares...

Continue Reading
WillScot Plans Upcoming Earnings Call and Webcast for Q1

Updated Category News Views 152

WillScot Holdings Corporation to Share Q1 Results WillScot Holdings Corporation, a renowned leader in providing innovative temporary flexible space solutions, has announced its schedule for releasing the financial results for the first quarter of 2025. This eagerly anticipated announcement is set to take place on May 1, 2025, after market close, allowing investors and...

Continue Reading
Denarius' Bold Move: Debentures Target Early Exit

Updated Category News Views 53

Treading Against Debentures: Denarius' Maneuver Denarius Metals Corp. doesn't seem keen on playing it safe with convertible debentures tying up its business. Jaw-dropping numbers in news like this make you stop and wonder: Is this strategy brilliance, or just a roll of the dice? Time-Pressured Decisions Denarius Metals, trading as OTCQX: DNRSF, has kicked off a whirlwind...

Continue Reading
Katten Partners Recognized Among Top Experts in Crypto Sector

Updated Category News Views 185

Katten Partners Shine in Crypto Industry Recognition Katten, a well-respected law firm, has gained significant attention for its leadership in the evolving digital asset landscape. Three of its distinguished partners have been recognized by Citywealth, a leading publication in the private wealth sector, for their exceptional contributions to the cryptocurrency domain. The...

Continue Reading
Anticipating Logitech International's Earnings Success

Updated Category News Views 160

Anticipating Logitech International's Earnings Success Logitech International (NASDAQ: LOGI) is gearing up for its next quarterly earnings announcement, and investors are keenly observing potential developments. As the company prepares to report earnings, expectations are high for positive news regarding financial forecasts and results. Analyst Predictions for Earnings...

Continue Reading